Quantcast

Latest Lupus Stories

2010-07-29 07:30:00

HAYWARD, Calif., July 29 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue,...

2010-07-27 12:33:29

Researchers at UT Southwestern Medical Center have uncovered the biological rationale for why large doses of corticosteroids given repeatedly over several weeks may help individuals with lupus, a chronic inflammatory disease that affects more than 1 million people in the U.S. Unlike the anabolic steroids athletes sometimes use illegally to bulk up muscle, corticosteroids are routinely used to treat inflammation in lupus patients. The drugs, however, can cause undesirable side effects...

2010-07-12 08:33:00

Findings Could Lead to Lower Doses of Medication for Lupus Patients, Reducing Serious Side Effects DALLAS, July 12 /PRNewswire-USNewswire/ -- Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute (BRI) in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide. Currently, those with lupus and other autoimmune diseases, commonly treat...

2010-07-08 08:00:00

EXTON, Pa., July 8 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends(®): Systemic Lupus Erythematosus (SLE). This report provides a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. in June. The difficulty in treating the complex, relapsing and remitting course of SLE is manifested in rheumatologists'...

2010-07-07 10:03:00

WASHINGTON, July 7 /PRNewswire/ -- The Lupus Foundation of America Greater Washington Chapter (LFAGW) has merged with Lupus Mid-Atlantic to serve the entire District of Columbia, Maryland, Northern and Central Virginia regions -- encompassing most of the tri-state area. Renamed the Lupus Foundation of America DC/MD/VA Chapter, Inc., services will include many support groups, two symposia, and free workshops and teleconferences. Potential patients served will increase to over 80,000 people...

2010-06-30 08:00:00

BRISBANE, Australia, June 30 /PRNewswire/ -- Australian drug development company CBio Limited (ASX: CBZ) today announced the achievement of a recruitment milestone in its clinical trial of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA). CBio Managing Director Jason Yeates said that the company was very pleased with recruitment levels achieved by the new clinical trial...

2010-06-24 14:50:49

Higher levels of antibodies may be linked to disease severity and progression University of Texas Medical Branch researchers have uncovered an association between free radical-mediated reactions and the severity and progression of system lupus erythematosus (SLE). Higher levels of oxidative and nitrosative stress markers were found in SLE patients with greater disease activity suggesting a causal relationship. Full findings of the study are available in the July issue of Arthritis &...

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM(TM), suggest promising results of epratuzumab in patients with SLE. EMBLEM(TM) was a 12-week,...

2010-06-15 07:00:00

EXTON, Pa., June 15 /PRNewswire/ -- BioTrends is pleased to announce the upcoming publication of a new syndicated report, TreatmentTrends®: Systemic Lupus Erythematosus (SLE). This report will provide a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. during the first week in June. Preliminary findings indicate that despite the availability of multiple treatment...

2010-06-10 13:42:00

HAYWARD, Calif., June 10 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has updated its Lupus Scientific Advisory Board. A-623 is Anthera's Phase 2b compound being developed as a treatment for systemic lupus erythematosus (SLE). "Anthera is developing a promising therapeutic for Lupus, a condition in great need of...


Latest Lupus Reference Libraries

10_727908da8421f900a92d7a25ed6718ea2
2004-10-19 04:45:44

Lupus (the wolf) Constellation -- Lupus belongs to the constellations of the Southern Hemisphere roughly between DECL=-30 degrees and DECL=-55 degrees and RA=14h 20m and RA=16h 15m, respectively. It is located between Centaurus on the western and Scorpius and Norma on the eastern boundary. In the north Lupus borders on Libra, to the south it tops Circinus. As a part of the Milky Way stretches through Lupus it is an interesting part of the sky for simple stargazing with binoculars....

More Articles (1 articles) »
Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related